Antithrombin III in cardiac surgery: an outcome study

Area of Science:

• Cardiovascular Surgery
• Anesthesiology
• Hematology

Background:

• Heparin resistance (HRP) poses challenges in surgical patients.
• Antithrombin III (ATIII) is crucial for heparin efficacy.
• Optimizing hemostasis in HRP is critical for patient outcomes.

Purpose of the Study:

• To evaluate the impact of lyophilized antithrombin III (ATIII) on patient outcomes in heparin-resistant patients (HRP).
• To compare outcomes between HRP treated with ATIII, HRP treated with increased heparin, and non-heparin-resistant controls.
• To investigate the influence of aminocaproic acid and timing of ATIII administration on outcomes.

Main Methods:

• Retrospective study of 311 patients from 12/15/95 to 10/24/96.
• Patients divided into three groups: HRP with increased heparin, HRP with ATIII, and non-HRP controls.
• Subgroup analysis of ATIII-treated patients based on aminocaproic acid use and timing of ATIII administration.

Main Results:

• No significant differences in postoperative coagulopathy or reoperation for bleeding between groups.
• Significant reduction in 24-hour chest tube drainage (CTD) (p=0.05) in HRP treated with ATIII and aminocaproic acid (419.37 ml vs. 782.88 ml and 766.67 ml).
• Significant differences observed in blood product usage (BPU) and intensive care unit stay (ICU-S) in other ATIII subgroups.

Conclusions:

• Early identification and treatment of HRP with ATIII and aminocaproic acid may decrease postoperative blood loss.
• This combined therapeutic approach shows promise in improving surgical outcomes for HRP.
• Further research may elucidate optimal protocols for ATIII and aminocaproic acid use in HRP.